Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.

scientific article published on 8 August 2017

Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1091101507
P356DOI10.1007/S10549-017-4430-2
P2888exact matchhttps://scigraph.springernature.com/pub.10.1007/s10549-017-4430-2
P932PMC publication ID5669824
P698PubMed publication ID28791495

P50authorYiwey ShiehQ81345889
Karla KerlikowskeQ92299671
P2093author name stringLin Ma
Elad Ziv
Steven R Cummings
Jeffrey A Tice
Donglei Hu
Scott Huntsman
Charlotte C Gard
Jessica W T Leung
P2860cites workPrevention of breast cancer in postmenopausal women: approaches to estimating and reducing riskQ28390064
Large-scale genotyping identifies 41 new loci associated with breast cancer riskQ29416989
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 statusQ30665329
Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort StudyQ33891825
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trialsQ34039907
Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancerQ34225990
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task ForceQ34339445
Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement.Q34372923
Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancersQ34764884
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guidelineQ34802964
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studiesQ35287715
Dense and nondense mammographic area and risk of breast cancer by age and tumor characteristicsQ35562818
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancerQ35996692
Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast CancerQ36090967
The contributions of breast density and common genetic variation to breast cancer riskQ36137764
Prediction of breast cancer risk based on profiling with common genetic variantsQ36583004
Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family RegistryQ36619329
Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective studyQ36673712
Testing for improvement in prediction model performance.Q36763246
Misuse of DeLong test to compare AUCs for nested modelsQ36933642
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive modelQ37172219
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical TrialsQ37351543
Mammographic density and risk of breast cancer by age and tumor characteristicsQ37690341
Obesity and the risk for premenopausal and postmenopausal breast cancerQ37990775
Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective studyQ38442766
Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast CancerQ39045823
Breast cancer risk prediction using a clinical risk model and polygenic risk scoreQ40605693
Circulating steroid hormone levels and risk of breast cancer for postmenopausal womenQ43189592
Serum estradiol level and risk of breast cancer during treatment with raloxifeneQ43846631
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studiesQ43963634
Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal womenQ45188730
Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).Q46116676
A breast cancer prediction model incorporating familial and personal risk factors.Q52000310
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.Q53585593
Projecting individualized probabilities of developing breast cancer for white females who are being examined annuallyQ69396132
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal womenQ79182457
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectestrogen-receptor positive breast cancerQ18553636
P304page(s)603-612
P577publication date2017-08-08
P1433published inBreast Cancer Research and TreatmentQ326085
P1476titleJoint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones
P478volume166

Reverse relations

cites work (P2860)
Q57748350Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study
Q93169632Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians
Q89746441Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field
Q64279327Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk
Q57074024Women's preferences, willingness-to-pay, and predicted uptake for single-nucleotide polymorphism gene testing to guide personalized breast cancer screening strategies: a discrete choice experiment

Search more.